CRO sector weakens, Puluo Pharmaceutical hits limit down.

The CRO sector weakened, with Apeloa Pharmaceutical hitting the limit down, Biocytogen, Innostellar Biotherapeutics, and Hite Biopharma falling over 10%, while Haofan Biology, Norsert, and Pharmaron also declined.